Search results for "From ACP Journal Club"

Results 1 - 10 of about 117 for "From ACP Journal Club".
Sort by: Relevance | Newest | Oldest

In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia

A reduction in hyperkalemia could allow use of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or aldosterone-receptor blockers in at-risk patients, justifying the prescribing of sodium-glucose cotransporter 2 (SGLT2) inhibitors, an ACP Journal Club commentary said.
16 Sep 2022

Patients surviving COVID-19 had increased risk for incident diabetes vs. persons without COVID-19

Although the effect of COVID-19 on diabetes incidence is small, according to the study, the affected population could be large, given that many at-risk people have had acute COVID-19, an ACP Journal Club commentary said.
12 Aug 2022

In diabetes, some statins reduce non–HDL-C better than others vs. placebo

A review reaffirmed well-known information about the potency of commonly prescribed statins and suggested that non–high-density lipoprotein cholesterol (HDL-C) may be a better measure of cardiovascular risk than low-density lipoprotein cholesterol in patients on statins, an ACP Journal Club commentary said.
12 Aug 2022

In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes

An analysis of recent manufacturer-sponsored studies of finerenone show it to be a potentially important new treatment for patients with type 2 diabetes and albuminuric chronic kidney disease (CKD), although it poses risk for serious hyperkalemia, an ACP Journal Club commentary said.
13 May 2022

Antihypertensive drugs reduced risk for new-onset type 2 diabetes; effect varies by antihypertensive class

The results of this individual-patient data meta-analysis suggest that angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers should be first-line antihypertensive agents in patients with prediabetes, an ACP Journal Club commentary said.
8 Apr 2022

In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status

The combination of efficacy and safety data from a recent placebo-controlled trial and other research shows sodium-glucose cotransporter-2 inhibitors to be an important treatment for heart failure with preserved ejection fraction (HFpEF) regardless of patients' diabetes status, according to an ACP Journal Club commentary.
14 Oct 2022

Some glucose-lowering drugs reduce HbA1c more than others

A recent meta-analysis supports the use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in patients with diabetes and elevated cardiovascular risk, but cost remains a barrier, an ACP Journal Club commentary said.
11 Dec 2020

In type 1 diabetes, real-time vs. intermittently scanned continuous glucose monitoring improved glycemic control

Clinicians can use the results of a recent European trial to reassure patients that good glycemic control can be achieved with either device, although real-time monitoring may be beneficial for those with more hypoglycemia issues, an ACP Journal Club commentary said.
8 Oct 2021

In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality

The results of the meta-analysis support recommendations to use sodium-glucose cotransporter-2 (SGLT2) inhibitors or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in diabetes patients who have or are at high risk for cardiovascular (CV) disease, an ACP Journal Club commentary said.
11 Mar 2022

In type 2 diabetes with increased CV risk, tirzepatide reduced HbA1c vs. glargine at 52 wk

Once tirzepatide is approved by the FDA, it may be a treatment option for patients with type 2 diabetes who are overweight, have high risk for atherosclerotic cardiovascular (CV) disease, and have no gastrointestinal symptoms, an ACP Journal Club summary said.
11 Mar 2022

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next